Considering the rapidly evolving treatment landscape of renal cell carcinoma (RCC), recent descriptions of the RCC population in the UK are lacking, as are real-world data on treatment and patient outcomes. To analyse the demographic and clinical characteristics, treatment patterns, and overall survival of patients with RCC using national data sets in England. This was a retrospective cohort study of patients diagnosed with RCC (all stages) between 2014-2018 using demographic, clinical, cancer registration, and treatment data. Patients were followed until death or study end (December 31, 2020). Treatments administered in each line were described to understand treatment sequencing. Kaplan–Meier methods were used for time-to-event analyses. Factors associated with discontinuation and survival were identified using Cox proportional hazard models. Among 32,577 included patients, the median age at diagnosis was 66 years, 63.4% were male, and 6,786 (20.8%) had metastatic RCC at diagnosis. Tyrosine kinase inhibitor (TKI) monotherapy was the most common treatment class across lines. Over three quarters of patients (78.5% [95% CI: 78.0-78.9]) were alive one year after diagnosis (93.2% in the non-metastatic at diagnosis subgroup and 37.1% among patients with metastases at diagnosis). At three years post initial diagnosis, 18.0% patients were alive in the metastatic at diagnosis subgroup. Rapid evolution of the treatment landscape limits the results regarding lines of therapy. This large-scale study provides insight on characteristics of patients with RCC, and it highlights the need for better treatment options to improve survival.

中文翻译：

---

英国肾细胞癌患者的患者特征、治疗模式和结果：一项回顾性队列研究

考虑到肾细胞癌 (RCC) 治疗格局的快速发展，英国缺乏对 RCC 人群的最新描述，以及治疗和患者结果的真实数据。使用英格兰国家数据集分析 RCC 患者的人口统计学和临床​​特征、治疗模式和总体生存率。这是一项回顾性队列研究，使用人口统计、临床、癌症登记和治疗数据，对 2014 年至 2018 年间诊断为 RCC（所有阶段）的患者进行。对患者进行随访直至死亡或研究结束（2020 年 12 月 31 日）。描述了每行中进行的治疗以了解治疗顺序。 Kaplan-Meier 方法用于事件发生时间分析。使用 Cox 比例风险模型确定了与停药和生存相关的因素。在纳入的 32,577 名患者中，诊断时的中位年龄为 66 岁，63.4% 为男性，6,786 名患者 (20.8%) 诊断时患有转移性肾细胞癌。酪氨酸激酶抑制剂（TKI）单一疗法是最常见的跨线治疗类别。超过四分之三的患者（78.5% [95% CI: 78.0-78.9]）在诊断后一年仍存活（诊断时非转移亚组中为 93.2%，诊断时有转移患者中为 37.1%）。初次诊断后三年，诊断时转移亚组中有 18.0% 的患者存活。治疗领域的快速发展限制了治疗方案的结果。这项大规模研究深入了解了肾细胞癌患者的特征，并强调需要更好的治疗方案来提高生存率。